指南与共识其他结缔组织病

美国风湿病学会儿童风湿病COVID-19大流行管理指南(第一版)

American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.
指南 / 共识 · Arthritis Rheumatol · 2020-09-28

该指南由美国风湿病学会组建的多学科工作组制定,针对儿童风湿病(PRD)患者在COVID-19大流行中的管理提出27条最终指导声明。基于文献回顾,指南指出PRD患儿似乎不增加SARS-CoV-2感染易感性,并作为「活文件」将随证据更新。

要点

  • PRD患儿似乎不增加SARS-CoV-2感染易感性。
  • 工作组采用改良Delphi法经3轮匿名投票形成27条最终指导声明。
  • 指南为「活文件」,将随COVID-19文献快速演变而更新。

核心结论

  • 基于现有文献回顾,PRD患儿似乎不增加对SARS-CoV-2感染的易感性。

研究设计与样本

  • 工作组由7名儿童风湿病学家、2名儿童感染病医师、1名成人风湿病学家和1名儿童执业护士组成,于2020年5月21日召集。
  • 基于患者、家庭及医疗提供者提出的问题起草临床问题和指导声明,生成证据报告分发给工作组成员。
  • 采用改良Delphi法进行3轮异步匿名电子邮件投票,使用9分数字评分系统并预设同意水平(1-3分不同意、4-6分不确定、7-9分同意)和共识水平(低、中、高)。

主要发现

  • 工作组起草了33条指导声明并在第二和第三轮投票中表决。
  • 33条声明的中位投票评分均位于同意最高三分位,其中6条为中度共识、27条为高度共识。
  • 将推荐相似的声明合并后,最终形成27条指导声明。

关键数值与推荐

  • 投票采用9分数字评分系统,中位评分1-3分为不同意、4-6分为不确定、7-9分为同意。
  • 共识水平分为低、中、高;指导声明获批需中位投票评分落在同意最高三分位且共识水平为中度或高度。

临床怎么用

  • 为治疗PRD患儿的风湿病提供者在COVID-19大流行背景下的临床管理提供指导。
  • 指南以「活文件」形式呈现,需关注未来基于COVID-19文献演变而更新的版本。

局限性

  • 指南基于当时可获得的文献回顾制定,而COVID-19文献正在快速演变,未来预计更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide clinical guidance to rheumatology providers who treat children with pediatric rheumatic disease (PRD) in the context of the coronavirus disease 2019 (COVID-19) pandemic. METHODS: The task force, consisting of 7 pediatric rheumatologists, 2 pediatric infectious disease physicians, 1 adult rheumatologist, and 1 pediatric nurse practitioner, was convened on May 21, 2020. Clinical questions and subsequent guidance statements were drafted based on a review of the queries posed by the patients as well as the families and healthcare providers of children with PRD. An evidence report was generated and disseminated to task force members to assist with 3 rounds of asynchronous, anonymous voting by email using a modified Delphi approach. Voting was completed using a 9-point numeric scoring system with predefined levels of agreement (categorized as disagreement, uncertainty, or agreement, with median scores of 1-3, 4-6, and 7-9, respectively) and consensus (categorized as low, moderate, or high). To be approved as a guidance statement, median vote ratings were required to fall into the highest tertile for agreement, with either moderate or high levels of consensus. RESULTS: The task force drafted 33 guidance statements, which were voted upon during the second and third rounds of voting. Of these 33 statements, all received median vote ratings within the highest tertile of agreement and were associated with either moderate consensus (n = 6) or high consensus (n = 27). Statements with similar recommendations were combined, resulting in 27 final guidance statements. CONCLUSION: These guidance statements have been generated based on review of the available literature, indicating that children with PRD do not appear to be at increased risk for susceptibility to SARS-CoV-2 infection. This guidance is presented as a "living document," recognizing that the literature on COVID-19 is rapidly evolving, with future updates anticipated.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol. 2020. PMID: 32705780. doi:10.1002/art.41455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。